NCT04928586View on ClinicalTrials.gov

Immunosuppressant Combined With Pirfenidone in CTD-ILD

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 16, 2019

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2025

Conditions
PirfenidoneConnective Tissue DiseasesInterstitial Lung Disease
Interventions
DRUG

Pirfenidone

CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose

DRUG

DMARDs

CTD-ILD patients treated with DMARDs according to the condition of the disease

Trial Locations (1)

250012

Qilu Hospital, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER